Financing ·
Maze Therapeutics exchanges 2.78M shares for pre-funded warrants with $0.001 exercise price
MAZEMaze Therapeutics, Inc.
On October 15, 2026, Maze Therapeutics entered into an exchange agreement with Frazier Life Sciences Public Fund and its affiliates to swap 2,776,007 shares of common stock for pre-funded warrants to purchase an equivalent number of shares. The warrants carry a nominal exercise price of $0.001 per share and are subject to beneficial ownership limitations capped at 9.99%. Following the transaction, outstanding common stock totaled approximately 53.9 million shares. Maze Therapeutics operates in the biotechnology industry, focusing on developing targeted therapies for cancer.